Trial Profile
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy Followed by 2 Cycles of Platinum-based Chemotherapy (Re-Check)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Re-Check
- 26 Sep 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 09 Oct 2019 Planned number of patients changed from 200 to 196.
- 10 Apr 2019 New trial record